The SRRM4 gene has been recently identified as a key protein responsible for a subtype of highly aggressive prostate cancers, called neuroendocrine prostate cancer (NEPC). Detection of SRRM4 protein in patient tumor biopsies is therefore important to predict and diagnose NEPC, so that early and more effective therapeutic means can be in place. Unfortunately, there is no SRRM4 antibody currently available that can be used for pathological analyses. This project will join force of academic and industrial expertise to develop a SRRM4 antibody that can be used in clinic for NEPC diagnosis.
Bladder Carcinoma (BC) is the fifth most common cancer in Canada. Although most individuals have surgery to remove BC tumors, the risk of another BC developing and/or progressing to invasive disease is high so long-term surveillance is necessary. The current method for screening for BC is not sensitive enough, and individuals often end up undergoing an unnecessary secondary procedure that is both uncomfortable and costly. In this project, we plan to design a diagnostic assay using urine samples, which will allow an easier and cost-effective method for early BC detection.
Targeted cancer therapies have significantly improved the treatment of leukemias, but emergence of treatment resistance and subsequent cancer relapse significantly reduces patient survival. This relapse is primarily caused by the inability of current therapies to eradicate leukemic stem cells. It is currently extremely challenging to study these stem cells, due to its rarity in patient blood samples.